Evidence map›Paper›PMID 26244496›Full record

ArticlePLoS pathogens2015

An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses.

Claire A Schreiber, Toshie Sakuma, Yoshihiro Izumiya, Sara J Holditch, Raymond D Hickey, Robert K Bressin, Upamanyu Basu, Kazunori Koide, Aravind Asokan, Yasuhiro Ikeda

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Casein kinase 2 activity is a host restriction factor for AAV transduction.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Claire A SchreiberDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Toshie SakumaDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Yoshihiro IzumiyaDepartment of Dermatology, UC Davis School of Medicine, Sacramento, California, United States of America.
Sara J HolditchDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Raymond D HickeyDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Robert K BressinDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Upamanyu BasuDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Kazunori KoideDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Aravind AsokanGene Therapy Center and Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Yasuhiro IkedaDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
WinnMed · USUniversity of Pittsburgh · USMayo Clinic · USUniversity of California, Davis · USUniversity of North Carolina at Chapel Hill · US

Funding

VECTOR AND MOLECULAR BIOLOGY COREP01HL112761 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MONAHAN, PAUL E · 2013 to 2017
$11.3M
Determinants of AAV TropismR01HL089221 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Aravind Asokan · 2009 to 2026
$8.1M
Regulated Long-Term Cardiac BNP Expression in Hypertensive Heart DiseaseR01HL098502 · NHLBI · MAYO CLINIC ROCHESTER · PI CATALIOTTI, ALESSANDRO, IKEDA, YASUHIRO · 2010 to 2014
$1.9M
K-Rta as a Novel SUMO and Epigenetic RegulatorR01CA147791 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO · 2010 to 2014
$1.5M
Chemical Approaches for the Discovery of New Cancer Therapeutic TargetsR01CA120792 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOIDE, KAZUNORI · 2006 to 2009
$755k
NCI NIH HHS R01 CA120792NCI NIH HHS R01 CA14779NCI NIH HHS R01 CA147791NHLBI NIH HHS P01 HL112761NHLBI NIH HHS P01HL112761NHLBI NIH HHS R01 HL089221NHLBI NIH HHS R01 HL098502
6 · The paper itself

Abstract

Adeno-associated viruses (AAV) have evolved to exploit the dynamic reorganization of host cell machinery during co-infection by adenoviruses and other helper viruses. In the absence of helper viruses, host factors such as the proteasome and DNA damage response machinery have been shown to effectively inhibit AAV transduction by restricting processes ranging from nuclear entry to second-strand DNA synthesis. To identify host factors that might affect other key steps in AAV infection, we screened an siRNA library that revealed several candidate genes including the PHD finger-like domain protein 5A (PHF5A), a U2 snRNP-associated protein. Disruption of PHF5A expression selectively enhanced transgene expression from AAV by increasing transcript levels and appears to influence a step after second-strand synthesis in a serotype and cell type-independent manner. Genetic disruption of U2 snRNP and associated proteins, such as SF3B1 and U2AF1, also increased expression from AAV vector, suggesting the critical role of U2 snRNP spliceosome complex in this host-mediated restriction. Notably, adenoviral co-infection and U2 snRNP inhibition appeared to target a common pathway in increasing expression from AAV vectors. Moreover, pharmacological inhibition of U2 snRNP by meayamycin B, a potent SF3B1 inhibitor, substantially enhanced AAV vector transduction of clinically relevant cell types. Further analysis suggested that U2 snRNP proteins suppress AAV vector transgene expression through direct recognition of intact AAV capsids. In summary, we identify U2 snRNP and associated splicing factors, which are known to be affected during adenoviral infection, as novel host restriction factors that effectively limit AAV transgene expression. Concurrently, we postulate that pharmacological/genetic manipulation of components of the spliceosomal machinery might enable more effective gene transfer modalities with recombinant AAV vectors.

Indexed as

Transduction, GeneticCarrier ProteinsCell LineDependovirusGenetic VectorsGenomic LibraryHost-Parasite InteractionsHumansImmunoblottingImmunoprecipitationMicroscopy, ConfocalReverse Transcriptase Polymerase Chain ReactionRibonucleoprotein, U2 Small NuclearRNA-Binding ProteinsRNA, Small InterferingSpliceosomesCarrier ProteinsPHF5A protein, humanRibonucleoprotein, U2 Small NuclearRNA-Binding ProteinsRNA, Small InterferingTrans-Activators

Identifiers

PMID26244496
PMCPMC4526370
OpenAlexW1699517913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.